Researchers at the University of Geneva, together with colleagues in Switzerland, France, the United States and Israel, describe how optogenetic control of brain cells and circuits is already steering both indirect neuromodulatory therapies and first-in-human retinal interventions for blindness, while sketching the practical and ethical conditions needed for wider clinical use.
Optogenetic control uses light to impose temporally precise gain or loss of function in specific cell types, or even individual cells. Selected by location, connections, gene expression or combinations of these features, researchers now have an unprecedented way to investigate the brain within living animals.
Modern experiments range from implanted fiber optics to three-dimensional holographic illumination of defined neuronal ensembles and noninvasive wearable LEDs, with interventions that can run from milliseconds to chronic use and effect sizes that change rapidly with changes in light intensity.
Such flexibility has turned optogenetics into a general tool that extends beyond the nervous system and into other organs, with more than 10,000 papers already reporting discoveries that use this approach. Recent work includes causal experiments on memory, decision-making and heart-to-brain communication, and circuit-level explorations rather than focusing on specific diseases.
In a Perspective article, “Roadmap for direct and indirect translation of optogenetics into discoveries and therapies for humans,” published in Nature Neuroscience, researchers describe how causal circuit experiments feed into two routes toward therapy, with optogenetic maps steering drugs and neuromodulation on one side and first-in-human retinal interventions for blindness on the other. They signal that future work will need to reckon with safety, regulation and ethics as discovery moves closer to clinical care.
Forging new circuit trails
One route from optogenetic experimentation to clinical use begins with basic circuit work that ties defined cell populations to specific neuropsychiatric symptoms. Understanding the bigger picture here could reveal methods to relieve symptoms.
After causal links are experimentally mapped and cells are described by location, gene expression and connections, drugs and stimulation technologies can target these populations without introducing genes or light into patients. Deep brain stimulation, transcranial magnetic stimulation, transcranial direct current stimulation and MRI-guided focused ultrasound can all be guided by optogenetic circuit findings.
Another path uses optogenetic results to build more precise descriptions of human brain function that may later support treatment design. Direct retinal work already shows how this can play out. Delivery of a channelrhodopsin gene and light to the retina of a blind patient with retinitis pigmentosa considerably improved visual perception. Nine similarly treated patients have shown no safety concerns so far, and at least four additional clinical trials are testing optogenetic vision restoration in different retinal cell types.
Where the path may lead
Common neuropsychiatric disorders are often collections of symptoms related to brain circuit activity. Symptoms such as anhedonia, compulsive behavior, social motivation and social cognition deficits, anxiety, post-traumatic stress reactions and psychosis have all been experimentally traced back to specific circuits.
Conditions like essential tremor, focal epilepsies, Parkinsonian motor control, end-stage retinitis pigmentosa and some forms of deafness have shown experimental potential for circuit-directed interventions.
Peripheral neuropathy, ALS, reflex sympathetic dystrophy, complex regional pain syndrome and bladder or bowel dysfunction after spinal injury are conditions not well served by current therapies and involve cellular targets more accessible to gene and light therapy, with intervention sites outside the brain.
Safety, regulation and ethics
Clinical use of optogenetics enters into a broader risk profile already seen with gene therapy. Viral vectors can trigger local immune responses in brain tissue through microglial activation and can also provoke systemic innate and adaptive responses that affect liver, blood vessels or other organs, especially at high doses. Safety concerns revolve around immune reactions to viral vectors, inflammation in nervous system tissue and the need to define acceptable dose limits.
Regulatory oversight treats optogenetic interventions as combinations of a biological product and a medical device. Retinal goggles, implantable or skull-mounted LEDs and any modified deep brain stimulation leads must satisfy device quality and performance standards alongside safety and dosing evaluations for the gene therapy component.
Ethical concerns follow the capacity of optogenetics to alter mood, motivation, memory and core survival drives like hunger, thirst, fear, aggression, mating and parenting. Cognitive liberty, defined as a right to mental self-determination, supports offering these interventions in severe disease when existing treatments fail. Neural data privacy, brain-related cybersecurity for patients, will create new ethical obligations as researchers explore interventions that go where there is no path.
Written for you by our author Justin Jackson, edited by Lisa Lock, —this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive.
If this reporting matters to you,
please consider a donation (especially monthly).
You’ll get an ad-free account as a thank-you.
More information
Christian Lüscher et al, Roadmap for direct and indirect translation of optogenetics into discoveries and therapies for humans, Nature Neuroscience (2025). DOI: 10.1038/s41593-025-02097-9
Journal information:
Nature Neuroscience
The content is provided for information purposes only.